Neurocrine Biosciences (NASDAQ:NBIX) Given New $155.00 Price Target at Cantor Fitzgerald

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective lowered by Cantor Fitzgerald from $170.00 to $155.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

Several other analysts also recently issued reports on NBIX. Robert W. Baird boosted their price objective on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an outperform rating in a report on Friday, August 2nd. Guggenheim raised their price objective on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a buy rating in a research note on Friday, August 2nd. Jefferies Financial Group boosted their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a buy rating in a research note on Monday, August 19th. Morgan Stanley raised their target price on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an overweight rating in a research report on Friday, July 12th. Finally, StockNews.com upgraded Neurocrine Biosciences from a buy rating to a strong-buy rating in a report on Sunday, August 4th. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $163.00.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $128.43 on Thursday. The company has a market capitalization of $12.92 billion, a P/E ratio of 35.38 and a beta of 0.37. Neurocrine Biosciences has a 1-year low of $103.63 and a 1-year high of $157.98. The business’s fifty day moving average price is $144.08 and its two-hundred day moving average price is $139.36.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The company had revenue of $590.20 million for the quarter, compared to analyst estimates of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. Neurocrine Biosciences’s revenue was up 30.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.95 EPS. On average, research analysts expect that Neurocrine Biosciences will post 4.22 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Julie Cooke sold 12,632 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the completion of the sale, the insider now directly owns 18,202 shares of the company’s stock, valued at approximately $2,789,638.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at approximately $5,499,554.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Julie Cooke sold 12,632 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $153.26, for a total value of $1,935,980.32. Following the completion of the sale, the insider now directly owns 18,202 shares of the company’s stock, valued at $2,789,638.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,798 shares of company stock worth $10,676,096. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. RFP Financial Group LLC boosted its position in shares of Neurocrine Biosciences by 346.5% in the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company’s stock worth $26,000 after purchasing an additional 149 shares during the last quarter. Mather Group LLC. acquired a new stake in Neurocrine Biosciences during the 1st quarter worth $26,000. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences during the second quarter worth about $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences in the second quarter valued at about $30,000. Finally, EdgeRock Capital LLC bought a new stake in shares of Neurocrine Biosciences in the fourth quarter worth about $31,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.